Prognostic factors and adjuvant systemic therapy for patients with HER2-positive T1N0 breast cancer: evidence from a real-world study with long-term follow-up

Gao, Songlin; Wang, Ding-Yuan; Wang, Xi; Zhang, Bo; Du, Feng; Ju, Jie; Yue, Jian; Kang, Yuan; Wang, Xue; Xu, Binghe; Yuan, Peng

doi:10.1007/s10549-022-06762-6

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In T1N0 HER2-positive BCs, the role of adjuvant trastuzumab is controversial. Age ≤ 40, T1c, and HR-positivity were identified as independent prognostic factors, and patients treated with CT plus trastuzumab could significantly benefit from the combination treatment despite observation or CT alone (hazard ratio 3.95 (p < 0.001) versus 2.70 (p = 0.034), respectively) [39]. In a retrospective analysis, adjuvant CT with trastuzumab was associated with improved DFS only in patients with T > 8 mm (>T1c) [40].…”

Section: Adjuvant Settingmentioning

confidence: 99%

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies

Tommasi,

Airò,

Pratticò

et al. 2024

JCM

View full text Add to dashboard Cite

Hormone receptor (HR)-positive/HER2-positive breast cancer represents a distinct subtype expressing estrogen and progesterone receptors with an overexpression of HER2. Approximately 14% of female breast cancer cases are HER2-positive, with the majority being HR-positive. These tumors show a cross-talk between the hormonal and HER2 pathways; the interaction has implications for the treatment options for the disease. In this review, we analyze the biology of HR-positive/HER2-positive breast cancer and summarize the evidence concerning the standard of care options both in neoadjuvant/adjuvant settings and in advanced disease. Additionally, we focus on new trials and drugs for HR-positive/HER2-positive breast cancer and the new entity: HER2-low breast cancer.

show abstract

Section: Adjuvant Settingmentioning

confidence: 99%